Journal
ACS OMEGA
Volume 6, Issue 20, Pages 13310-13320Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsomega.1c01289
Keywords
-
Categories
Funding
- Chemestmed, Ltd.
Ask authors/readers for more resources
Two new ALKBH5 inhibitors were found to significantly suppress the proliferation of leukemia cell lines, with IC50 values ranging from 1.38 to 16.5 μM. However, the effect on another leukemia cell line and glioblastoma cell line was minimal. This demonstrates the potential of ALKBH5 inhibition as a selective antiproliferative strategy for certain cancer cell types.
The RNA 6-N-methyladenosine (m6A) demethylase ALKBH5 has been shown to be oncogenic in several cancer types, including leukemia and glioblastoma. We present here the target-tailored development and first evaluation of the antiproliferative effects of new ALKBH5 inhibitors. Two compounds, 2-[(1-hydroxy-2-oxo-2-phenylethyl)sulfanyl]acetic acid (3) and 4-{[(furan-2-yl)methyl]amino}-1,2-diazinane-3,6-dione (6), with IC50 values of 0.84 mu M and 1.79 mu M, respectively, were identified in high-throughput virtual screening of the library of 144 000 preselected compounds and subsequent verification of hits in an m6A antibody-based enzyme-linked immunosorbent assay (ELISA) enzyme inhibition assay. The effect of these compounds on the proliferation of selected target cancer cell lines was then measured. In the case of three leukemia cell lines (HL-60, CCRF-CEM, and K562) the cell proliferation was suppressed at low micromolar concentrations of inhibitors, with IC50 ranging from 1.38 to 16.5 mu M. However, the effect was low or negligible in the case of another leukemia cell line, Jurkat, and the glioblastoma cell line A-172. These results demonstrate the potential of ALKBH5 inhibition as a cancer-cell-type-selective antiproliferative strategy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available